Abstract
Adverse drug reactions (ADRs) are a challenge in modern healthcare, particularly due to the increasing complexity of therapeutics, more and more ageing population, and the rising of multimorbidity. Adverse drug reactions are a significant cause of hospitalizations and deaths worldwide. It’s estimated that about 1/3 of the patients’ death each year worldwide were caused by unreasonable medications. Statistical data show that, in China, about 2.5 million patients were hospitalized each year due to adverse drug reactions, approximately 200,000 people died directly because of unreasonable medication. The incidence of adverse drug reactions in adults is \(6.9\%\), in children this rate is \(12.9\%\), and in newborns this rate is as high as \(24.4\%\). Unreasonable medications happened frequently to newborns, because they are easy to have greater impacts on children, the younger the children are, the more serious the adverse drug reactions are. Therefore, it’s very important to find solutions to avoid ADRs occurring to reduce the risk of their harm to patients. Pharmacogenomics is the study of how genes affect a person’s response to drugs, therefore, in this paper, based on pharmacogenomics, we established a system to provide individualized medication guidance including dosage recommendations, or withdrawal of the drugs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Aronson, J.K., Ferner, R.E.: Clarification of terminology in drug safety. Drug Saf. 28, 851–70 (2005). https://doi.org/10.2165/00002018-200528100-00003
Ferner, R.E., Aronson, J.K.: Preventability of drug-related harms-part I: a systematic review. Drug Saf. 33, 985–994 (2010). https://doi.org/10.2165/11538270-000000000-00000
Coleman, J.J., Pontefract, S.K.: Adverse drug reactions. Clin. Med. 16, 481–5 (2016)
Manolio, T.A.: Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. v363, 166–176 (2010)
Wang, L., Howard, L., et al.: Genomics and drug response. N. Engl. J. Med. 364, 1144–1153 (2011)
Thorn, C., Klein, T., Altman, R.B.: PharmGKB: the pharmacogenomics knowledge base. Methods Mol. Biol. 1015, 311–320 (2013)
Altman, R.B., Klein, T.E.: Challenges for biomedical informatics and pharmacogenomics. Ann. Rev. Pharmacol. Toxicol. 42, 113–133 (2002)
Povey, S., Lovering, R., Bruford, E., Wright, M., Lush, M., Wain, H.: The HUGO gene nomenclature committee (HGNC). Hum. Genet. 109(6), 678–680 (2001). https://doi.org/10.1007/s00439-001-0615-0
Wishart, D.S., Knox, C., et al.: DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34, D668–D672 (2006)
Eichelbaum, M., Altman, R.B., et al.: New feature: pathways and important genes from PharmGKB. Pharmacogenet. Genomics 19, 403 (2009)
Sangkuhl, K., Berlin, D.S., et al.: PharmGKB: understanding the effects of individual genetic variants. Drug Metab. Rev. 40, 539–551 (2008)
The Human Genome Project. https://www.genome.gov/human-genome-project. Accessed 22 May 2020
Pharmacogenomics Knowledgebase. https://www.pharmgkb.org/. Accessed 31 May 2020
HUGO Gene Nomenclature Committee. https://www.genenames.org/. Accessed 31 May 2020
DrugBank. https://www.drugbank.ca/. Accessed 31 May 2020
Lamba, J., Hebert, J.M., et al.: PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet. Genomics 22(7), 555–8 (2012)
Clinical Pharmacogenetics Implementation Consortium. https://cpicpgx.org/. Accessed 31 May 2020
Pharmacogenomics Research Network. https://www.pgrn.org/. Accessed 31 May 2020
Dutch Pharmacogenetics Working Group (DPWG). http://upgx.eu/guidelines/. Accessed 31 May 2020
Technical Guidelines for the Genetic Testing of Drug Metabolizing Enzymes and Drug Targets. http://www.nhc.gov.cn/yzygj/s7659/201507/ 03e00d45538d43babe62729a8f635ff7.shtml. Accessed 31 May 2020
Workflow Description Language (WDL). https://github.com/openwdl/wdl. Accessed 31 May 2020
Cromwell-Workflow Management System. https://github.com/broadinstitute/cromwell. Accessed 6 June 2020
Whirl-Carrillo, M., McDonagh, E.M., et al.: Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92(4), 414–7 (2012)
Schwarz, U.I., Ritchie, M.D., et al.: Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358(10), 999–1008 (2008)
Acknowledgment
This work was partially supported by the Science Foundation of Beijing Language and Culture University (supported by “the Fundamental Research Funds for the Central Universities”) (20YJ040007, 19YJ040010, 17YJ0302)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this paper
Cite this paper
Yang, J., Li, B. (2020). Individualized Medication Guidance Based on Pharmacogenomics. In: Huang, Z., Siuly, S., Wang, H., Zhou, R., Zhang, Y. (eds) Health Information Science. HIS 2020. Lecture Notes in Computer Science(), vol 12435. Springer, Cham. https://doi.org/10.1007/978-3-030-61951-0_17
Download citation
DOI: https://doi.org/10.1007/978-3-030-61951-0_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-61950-3
Online ISBN: 978-3-030-61951-0
eBook Packages: Computer ScienceComputer Science (R0)